CTXR — Citius Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Citius Pharmaceuticals Announces Efficacy And Safety Data For Its I/Ontak (E7777) Phase 3 Study
U.S. STOCKS ON THE MOVE-Heartbeam, Aura Biosciences, U.S. banks
Citius Pharma up on submitting marketing application for blood disorder drug
Brief: Citius Pharma Reports Clinical Collaboration With University Of Pittsburgh
Citius Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results And Provides Business Update
Citius Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Citius Pharmaceuticals Holds Pre-BLA Meeting With The FDA For I/Ontak
Brief: Citius Pharma To Spinoff Late-Stage Oncology Asset, I/ONTAK, Into New Standalone Publicly Traded Company
Citius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Citius Pharmaceuticals Reports Fiscal Q2 2022 Results
Citius Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview
Citius rises on expanding trial sites outside U.S.
Brief: Citius Pharma Enrolls First Patient In Study Of Halo-Lido For Prescription Treatment Of Hemorrhoids
Brief: Citius Pharmaceuticals Says Leonard Mazur Named Chairman And CEO
U.S. STOCKS ON THE MOVE-Mosaic, Advent Tech, COVID vaccine makers
U.S. STOCKS ON THE MOVE-NextDecade, U.S. banks, Hyzon Motors
U.S. STOCKS ON THE MOVE-Stellantis, Array, Big Tech
U.S. STOCKS ON THE MOVE-Gogo, JetBlue, Twitter